A Clinical and Sero-Epidemiological Study of 190 Belgian Patients Suffering from Lyme Borreliosis (original) (raw)
Related papers
Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe
Clinical Microbiology and Infection, 2011
Lyme borreliosis, caused by spirochaetes of the Borrelia burgdorferi genospecies complex, is the most commonly reported tick-borne infection in Europe and North America. The non-specific nature of many of its clinical manifestations presents a diagnostic challenge and concise case definitions are essential for its satisfactory management. Lyme borreliosis is very similar in Europe and North America but the greater variety of genospecies in Europe leads to some important differences in clinical presentation. These new case definitions for European Lyme borreliosis emphasise recognition of clinical manifestations supported by relevant laboratory criteria and may be used in a clinical setting and also for epidemiological investigations.
Longitudinal study of Lyme borreliosis in a high risk population in Switzerland
Parasite (Paris, France), 1998
Orienteers from all parts of Switzerland (n = 416) were included in a longitudinal study for Lyme borreliosis. In spring 1986, the seroprevalence was 28.1%. At the beginning of the study, 84.3% of orienteers reported a history of tick bite, and 3.8% reported a past history of Lyme borreliosis. During the first (spring 1986-autumn 1986), second (autumn 1986-spring 1987) and third (spring 1987-autumn 1987) period, rates of seroconversion were 0.6%, 2.7% and 2.1% respectively. During the first and second period, clinical incidence were 1.0% and 0.25% respectively. No active Lyme borreliosis was detected during the third period. Among orienteers who seroconverted during the study (n = 16), only two developed clinical symptoms. Hence, Borrelia burgdorferi infection is often asymptomatic.
Incidence and hospitalisation rates of Lyme borreliosis, France, 2004 to 2012
Eurosurveillance, 2014
Lyme borreliosis (LB) has become a major concern recently, as trends in several epidemiological studies indicate that there has been an increase in this disease in Europe and America over the last decade. This work provides estimates of LB incidence and hospitalisation rates in France. LB data was obtained from the Sentinelles general practitioner surveillance network (2009-2012) and from the Programme de Médicalisation des Systèmes d'Information (PMSI) data processing centre for hospital discharges (2004-09). The yearly LB incidence rate averaged 42 per 100,000 inhabitants (95% confidence interval (CI): 37-48), ranging from 0 to 184 per 100,000 depending on the region. The annual hospitalisation rate due to LB averaged 1.55 per 100,000 inhabitants (95% CI: 1.42-1.70). Both rates peaked during the summer and fall and had a bimodal age distribution (5-10 years and 50-70 years). Healthcare providers should continue to invest attention to prompt recognition and early therapy for LB, whereas public health strategies should keep promoting use of repellent, daily checks for ticks and their prompt removal.
Revue d'Épidémiologie et de Santé Publique, 2010
Lyme borreliosis (LB) has become a major concern recently, as trends in several epidemiological studies indicate that there has been an increase in this disease in Europe and America over the last decade. This work provides estimates of LB incidence and hospitalisation rates in France. LB data was obtained from the Sentinelles general practitioner surveillance network (2009-2012) and from the Programme de Médicalisation des Systèmes d'Information (PMSI) data processing centre for hospital discharges (2004-09). The yearly LB incidence rate averaged 42 per 100,000 inhabitants (95% confidence interval (CI): 37-48), ranging from 0 to 184 per 100,000 depending on the region. The annual hospitalisation rate due to LB averaged 1.55 per 100,000 inhabitants (95% CI: 1.42-1.70). Both rates peaked during the summer and fall and had a bimodal age distribution (5-10 years and 50-70 years). Healthcare providers should continue to invest attention to prompt recognition and early therapy for LB, whereas public health strategies should keep promoting use of repellent, daily checks for ticks and their prompt removal.
Clinical and epidemiological features of Lyme borreliosis in Bulgaria
Wiener Klinische Wochenschrift, 2004
Introduction: Data on disease expression and epidemiological characteristics of Lyme borreliosis in southeastern Europe are scarce. Patients: To reveal features of Lyme borreliosis in Bulgaria, clinical data and epidemiological characteristics of 1257 patients reported between 1999 and 2002 were analysed. Results: The most affected age group was 5-9 years, followed by 45-49 years, 50-54 years, and 10-14 years. Most of the patients (68%) lived in a rural area or were attacked by ticks during activities in a rural area. Lyme borreliosis cases occurred throughout the year with two peaks-one in June and second smaller one in September. The most common clinical manifestation was erythema migrans (EM), diagnosed in 868 (69.1%) of the patients. Rashes had a median diameter of 11 cm and were predominantly located on lower extremities. Forty-four per cent of the rashes consisted of homogenous erythema and 56% had central clearing. Multiple EM was detected in 4.3% of the EM cases. Neuroborreliosis was the second most common presentation of Lyme borreliosis, diagnosed in 19% of the patients. Lyme arthritis was found in 8% of the patients. Heart and ocular manifestations were recorded in 1.1% and 0.9% of the patients, respectively. Borrelial lymphocytoma and acrodermatitis chronica atrophicans were very rare (0.3%). Twentyseven patients (2.1%) had multiple organ involvement. Conclusions: The results of the study show that the epidemiology and clinical manifestations of Lyme borreliosis in Bulgaria are similar to those in the majority European countries but possess some distinguishing characteristics.
Lyme Borreliosis: Clinical Manifestations and Advances in Diagnosis and Control
Journal of Experimental Biology and Agricultural Sciences, 2020
Lyme disease or borreliosis is presumed one of the most significant vector-borne diseases globally. The disease is re-emerging in numerous parts of world. It has expanded dramatically in newer areas in recent decades. Lyme disease is caused by Borrelia burgdorferi yet additionally by other borrelial species, B. afzelii and B. garini which cause diverse clinical syndromes. Spatial distribution and clinical presentations differ depending on the causative species. Clinical manifestations of Lyme disease can be delineated in three stages. The first stage is presented in the form of erythema migrans at the site of tick bite. Early dispersed stage can lead to multiple lesions of erythema migrans, neuroborreliosis, lymphocytoma, arthritis or carditis. The manifestation at later stage shows acordermatitis chronica atrophicans, arthritis and neurological involvement. Diagnosis is challenging owing the several clinical presentations and could require multiple tests. The antibiotics that are c...
International Journal of Innovative Research in Technology, 2021
Lyme infection or Lyme borreliosis is a spirochetosis sent by tick chomp. The most well-known clinical sign is erythema migrans. It is the most wellknown tick-borne sickness in the northern half of the globe. It is a fundamental sickness, brought about by a whip bacterium near treponema pallidum syphilis of the variety Borrelia burgdorferi sensu lato (basically B. garinii, B. afzelii, B. burgdorferi sensu stricto), sent by the nibble of a tick of the variety (Ixodes ricinus in Europe). The microbe can spread haematogenous to different tissues and organs, including essentially the sensory system, joints, and skin. Finding depends on anamnestic, clinical and natural contentions. Organic tests, mostly dependent on serology, are fundamental for the conclusion of the sickness, except for erythema migrans, the finding of which should remain rigorously clinical. The treatment depends on the utilization of one of the accompanying 3 classes of anti-toxins: β-lactams, cyclins or macrolides, for a span of 2 to about a month relying upon the clinical setting. Notwithstanding the insurance against tick nibbles, the best individual preventive measure is, if there should arise an occurrence of openness, early discovery and evacuation of ticks joined to the skin.